Therapy News and Research

RSS

Innovative vaccine therapy shows promise against glioblastoma brain tumors

An innovative vaccine therapy developed at Roswell Park Cancer Institute is being tested in a multisite clinical trial involving 50 patients with newly diagnosed glioblastoma brain tumors. The phase II study, now accruing patients at both Roswell Park and the Cleveland Clinic, will assess the effectiveness of the SurVaxM vaccine in combination with standard chemotherapy as treatment for this often-fatal cancer.

10 Sep 2015

Latest edition of ‘The Menopause Guidebook’ helps women looking for answers to common questions

There is much debate surrounding how a woman entering the stages of menopause, or in the throes of this life stage, can or should manage symptoms, and now there are more options than ever before, adding extra confusion to the mix.

10 Sep 2015

Liver failure patients may benefit from CSF-1 treatment that aids the immune system to combat infections

Patients with liver failure could benefit from a treatment that helps the immune system to combat infections linked to the condition, research suggests.

10 Sep 2015

Nerve damage caused by leprosy linked to changes in the brain of patients

Brain plasticity is the ability of the brain to change both anatomically and functionally in response to changes in the body or in the environment.

10 Sep 2015

Simple stem cell production method shows promise in mice for treating IPF

In a small pilot study, researchers from North Carolina State University have demonstrated a rapid, simple way to generate large numbers of lung stem cells for use in disease treatment. This method of harvesting and growing a patient's own lung stem cells shows promise in mice for treating idiopathic pulmonary fibrosis (IPF), and could one day provide human IPF sufferers with an effective, less invasive method of treatment for their disease.

10 Sep 2015

HUCBC-derived monocytes diminishes Aβ pathology, improves cognition in AD modeled mice

Alzheimer's disease (AD), which affects an estimated 26 million people worldwide, is the fourth leading cause of death among the elderly and the leading cause of dementia. Predictions are that the number of AD cases will quadruple by 2050.

9 Sep 2015

Upfront combination therapy fulfils AMBITION in PAH patients

Upfront treatment with the combination of ambrisentan and tadalafil improves outcomes in patients with pulmonary arterial hypertension more than either treatment as monotherapy, shows a randomised trial.

9 Sep 2015

PAH treatments less effective in CTD-associated disease

Patients with connective tissue disease-associated pulmonary arterial hypertension have a poorer response to advanced PAH treatments than those with idiopathic disease, finds a meta-analysis.

9 Sep 2015

Myriad Genetics presents two posters on myPlan Lung Cancer prognostic test at WCLC 2015

Myriad Genetics, Inc. today presented two posters on its myPlan Lung Cancer prognostic test at the International Association for the Study of Lung Cancer 16th World Conference on Lung Cancer being held in Denver, Colo.

9 Sep 2015

Latest ENT research to be presented at AAO-HNSF's annual meeting

The latest research on hearing loss, head and neck cancers, sleep apnea and other otolaryngic topics will be presented in Dallas, TX, September 27-30, at the 2015 Annual Meeting & OTO EXPO? of the American Academy of Otolaryngology--Head and Neck Surgery Foundation (AAO-HNSF), the largest annual meeting of ear, nose, throat, head and neck physicians in the world.

9 Sep 2015

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery.

9 Sep 2015

New statistical model may help predict patients more likely to benefit from surgical treatment for mesothelioma

A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma (MPM), according to an article in the September 2015 issue of the Annals of Thoracic Surgery.

9 Sep 2015

New study reveals conflicting role of two subtypes of pancreatic cancer stroma

Dense surrounding tissue can block drugs from reaching pancreatic cancer tumors, but it can also help prevent the cancer from spreading. Now a new study by UNC Lineberger Comprehensive Cancer Center researchers and collaborators helps explain the conflicting role of the surrounding tissue known as stroma. In the study, the researchers revealed that based on molecular characteristics, there are two subtypes of pancreatic cancer stroma.

9 Sep 2015

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

The University of Pennsylvania's Abramson Cancer Center (ACC) has received an "exceptional" rating by the National Cancer Institute during an extensive peer-review process for its five-year competitive research support grant. The rating is the highest possible for an NCI cancer center.

9 Sep 2015

UCSF researchers lead $10 million research project on pediatric cancer

Researchers at UC San Francisco are leading a five-year, $10 million research project dedicated to pediatric cancer, funded by the first grant of its kind to focus on a molecular pathway that underlies many cancers rather than on a cancer in a particular organ or tissue in the body.

9 Sep 2015

Children's Cancer Institute awarded NCI grant to fast-track new drugs into clinical trials for childhood cancer

Children's Cancer Institute welcomes its inclusion, by the US National Cancer Institute (NCI), in a systematic program of drug evaluation in childhood cancer.

9 Sep 2015

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

The Drugs for Neglected Diseases initiative (DNDi) has announced today at the 9th European Congress on Tropical Medicine and International Health in Basel, Switzerland, the successful completion of Phase I human clinical trials for SCYX-7158 (AN5568), the first oral drug candidate specifically developed from the earliest drug discovery stage to combat human African trypanosomiasis, or sleeping sickness, a deadly parasitic disease transmitted by the tsetse fly.

9 Sep 2015

Survival and health outcomes for extremely preterm infants improve over 20 years

Over the last 20 years, complications have decreased and survival has improved for extremely preterm infants, according to a study in the September 8 issue of JAMA.

9 Sep 2015

Struggling to live with lung cancer

New data show that more than 50% of patients and carers struggled to cope with challenges of living with lung cancer.

8 Sep 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

Therapy News and Research

Innovative vaccine therapy shows promise against glioblastoma brain tumors

Latest edition of ‘The Menopause Guidebook’ helps women looking for answers to common questions

Liver failure patients may benefit from CSF-1 treatment that aids the immune system to combat infections

Nerve damage caused by leprosy linked to changes in the brain of patients

Simple stem cell production method shows promise in mice for treating IPF

HUCBC-derived monocytes diminishes Aβ pathology, improves cognition in AD modeled mice

Upfront combination therapy fulfils AMBITION in PAH patients

PAH treatments less effective in CTD-associated disease

Myriad Genetics presents two posters on myPlan Lung Cancer prognostic test at WCLC 2015

Latest ENT research to be presented at AAO-HNSF's annual meeting

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

New statistical model may help predict patients more likely to benefit from surgical treatment for mesothelioma

New study reveals conflicting role of two subtypes of pancreatic cancer stroma

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

UCSF researchers lead $10 million research project on pediatric cancer

Children's Cancer Institute awarded NCI grant to fast-track new drugs into clinical trials for childhood cancer

DNDi announces successful completion of SCYX-7158 Phase I study for treatment of sleeping sickness

Survival and health outcomes for extremely preterm infants improve over 20 years

Struggling to live with lung cancer

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News